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Background: Circumstantial evidence suggests that conjugated linoleic acid (CLA) beneficially modulates
immune function in allergic subjects. C9,t11-CLA, naturally occurring in ruminant fats, is suggested to be the
effective isomer. In contrast, for the t10,c12-CLA isomer, which is naturally found only in traces but usually
constitutes a relevant part in commercial CLA mixtures, adverse effects have been reported. Aim of this study
was to assess putative immunomodulatory effects of highly enriched c9,t11-CLA in allergic subjects. To our
best knowledge, our study is the first in that a CLA preparation was used for such purpose which was free of
t10,c12-CLA.
Design: Twenty-nine asthmatic children and adolescents (age 6–18 y) with diagnosed allergic sensitization against
grass pollen, house dust mite, or cat hair/epithelia consumed daily a portion of yoghurt containing either 3 g CLA
(75 % c9,t11-CLA, 87 % purity) or placebo (safflower oil) over a period of 12 weeks. At study start and end, lung
function parameters, specific IgE, in vitro allergen-induced cytokine production in peripheral blood mononuclear cells
(PBMC), plasma ECP, urinary 8-oxodG as marker of oxidation, fatty acid profiles of erythrocytes, and routine
haematological parameters were determined. Prior to blood samplings, 3-days dietary records were requested.
Throughout the study, the participants documented daily their peak expiratory flow and kept protocol about their
allergy symptoms and usage of demand medication.
Results: In contrast to the CLA group, PBMC-produced IFN-γ and IL-4 increased significantly and by trend, respectively,
in the placebo group. Moreover, plasma ECP tended to increase in the placebo group. In the pollen subgroup, FEV1
improved upon both CLA and placebo oil supplementation. In both intervention groups, the n-6/n-3 PUFA ratio in red
blood cells decreased, mainly due to an increase in n-3 PUFA. Moreover, 8-oxodG excretion increased in both groups.
No changes occurred regarding specific IgE concentrations, allergy symptoms, and volume parameters.
Conclusion: Our results indicate that CLA modestly dampens the inflammatory response on the cellular level. A
clinically relevant amelioration of the symptoms could not be proved in atopic manifest patients.
Trial registration: NCT01026506.
Keywords: Asthma, Allergy, Children, Conjugated linoleic acid, Cytokines* Correspondence: anke.jaudszus@mri.bund.de
1Present Address: Department of Physiology and Biochemistry of Nutrition,
Max Rubner-Institut, Federal Research Institute of Nutrition and Food,
Haid-und-Neu-Straße 9, D-76131 Karlsruhe, Germany
Full list of author information is available at the end of the article
© 2016 Jaudszus et al. Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Demographic data and baseline characteristics of the
study participants
Parameter Placebo CLA
n (female/male) 13 (8/5) 15 (5/10)
Age (y), median (range) 13 (7–18) 13 (6–17)
Age groups, n (% all participants)
6–12 4 (14) 6 (21)
13–18 9 (32) 9 (32)
BMI (kg/m2)a, median (range) 19.5 (15.3–29.0b) 19.9 (14.7c-23.5)
Major allergen, n (% group participants)
Phl p1 6 (46) 7 (47)
Der p1 4 (31) 5 (33)
Fel d1 3 (23) 3 (20)
FEV1 % predicted, median (range) 97 (70–126) 95 (83–122)
aAdjusted for clothing
b> Percentile 97
c< percentile 3 of age- and sex-specific range, according to
Kromeyer-Hauschild [54]
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Over the last decades, the incidence of allergic airway
diseases such as allergic rhinitis and bronchial asthma
has rapidly increased in industrialized countries and
currently affects up to 30 % of the population in
Germany. In 2008, the direct medical care costs as-
cribed to asthma accounted for EUR 1.8 billion [1],
thus constituting a substantial economic burden. This
epidemic trend, which is continuing to rise, has been
related to lifestyle changes typical of westernization,
such as hygiene, an indoor life, reduced physical ac-
tivity, and a modified diet. In particular, for the diet
hypothesis, epidemiological and cross-sectional evi-
dence has been relatively consistent in suggesting that
an unbalanced high intake of n-6 polyunsaturated
fatty acids (n-6 PUFA) such as linoleic acid (LA) may
contribute to the incidence of allergic sensitization
and asthma (reviewed in [2] and [3]). Research inter-
est increasingly focuses on dietary fats and their detri-
mental as well as their beneficial roles in the
development of diseases. For instance, the consump-
tion of full cream milk and butter from early child-
hood on was found to be inversely associated with
the onset of allergic asthma [4, 5]. Dairy fat, espe-
cially that of ruminants being pastured, is the main
source of conjugated linoleic acids (CLA), a class of
unsaturated fatty acids that comprises several pos-
itional and geometrical isomers [6]. We have previ-
ously shown that the predominant natural CLA
isomer c9,t11-CLA reduces expression of the chemo-
kine interleukin (IL)-8 in airway epithelial cells [7],
inhibits IL-2 and tumor necrosis factor (TNF)-α in T-
helper cells [8], and prevents experimentally induced
airway inflammation in mice at least in part via a
peroxisome proliferator-activated receptor gamma
(PPARγ)-dependent mechanism [9]. Based on the
in vitro experiments and the data obtained from the
animal model, the present pilot study was conducted
to investigate the effects of a dietary intervention with
CLA on clinical and immunological parameters in
children and adolescents with allergic bronchial
asthma. Epidemiological studies indicate that patients
with chronic diseases often turn to alternative or
complementary therapeutic strategies, including diet-
ary supplements [10]. Especially for mild asthmatic
children non-pharmacologic interventions could be at-
tractive. Thus, the aims of the study were 1) To provide
proof of principle for therapy-supporting usage of CLA in
mild asthmatic children, e.g., improvement of asthma
symptoms and reduction of inflammatory markers; 2) To
assess the clinical efficacy of the CLA treatment, e.g., re-
duction of demand medication; and 3) To demonstrate
whether potential beneficial effects are specific for the
CLA treatment (comparison with placebo oil). Thenovelty of this study is that we used a CLA triacylglycerol
preparation which exclusively contained the naturally
occurring 9,11-isomers of CLA.
Methods
Subjects, study design and study oils
Twenty-nine children and adolescents (13 girls, 16 boys;
age 6–18 years) with diagnosed bronchial asthma were
recruited from the Outpatient Clinic for Pediatric Aller-
gology and Pneumology of the Jena University Hospital
(Table 1). Eligibility criteria were: allergic sensitization
against timothy grass pollen (Phl p1, seasonal allergen
exposure), house dust mite, or cat hair/epithelia (Der p1,
Fel d1, exposure irrespective of season) to comprise both
seasonal and all-year allergy; specific IgE ≥0.7 IU/L
(ImmunoCAP, Phadia, Uppsala, Sweden) at screening or
within the past 12 month; mild to moderate course of dis-
ease defined as clinical stability and mean forced expira-
tory volume in 1 s (FEV1) ≥70 % of predicted at screening;
competence regarding the daily documentation of PEF
data and of allergy symptoms. Exclusion criteria were: pri-
mary and secondary immune deficiency; specific immune
therapy within the past 2 years; treatment with anti-IgE-
antibodies; regular intake of systemic steroid medication;
intolerance against dairy products; obesity (BMI ≥30 kg/
m2); participation in another study. Before inclusion, writ-
ten informed consent was obtained from all participants/
parents. A total of 28 subjects finished the study (Fig. 1).
The study was designed as a prospective and placebo-
controlled pilot trial. After a 1-week run-in period to as-
certain the current state of disease, categorization of
allergic sensitization, and delivery of the patient’s diaries,
of the bins for collecting the 24 h-urine, and of the 3-
days dietary record templates, the participants were
Fig. 1 Flow diagram of the study participants recruited and allocated to the study groups, and the design of the study
Table 2 Fatty acid profiles of the study oils [% FAME].
Combined GC-FID and silver-ion HPLC analysisa
Fatty acid (common name) CLA Placebo oil
C14:0 (myristic acid) 0 0.1
C16:0 (palmitic acid) 0.1 8.2
C18:0 (stearic acid) 0.5 3.4
C18:1c9 (oleic acid) 1.8 19.9
C18:1c11 (vaccenic acid) 0.3 0
C18:2n-6 (linoleic acid) 3.1 64.5
C18:3n-3 (alpha-linolenic acid) 0.2 1.0
C20:0 (arachidic acid) 0.1 0.5
C20:1 (eicosenoic acid) 0.5 0.3
C20:5n-3 (eicosapentaenoic acid) 0 0
Other 6.8 2.3





aFor detailed information, please refer to [11]
bCorrected for co-eluting t8,c10
cCorrected for co-eluting t8,t10
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tention to a balanced distribution regarding age and type
of allergy (Fig. 1, Table 1). Participants, clinicians, and
lab assistants had no information on the group assign-
ment. Throughout the intervention period of 12 weeks,
the participants consumed daily either 3 g of an esteri-
fied 9,11-CLA preparation free of t10,c12-CLA (75 %
c9,t11-CLA, 87 % purity [11]) or 3 g of a placebo oil
(Table 2) mixed in 100 g portions of commercial low-fat
yoghurt (0.1 % milk fat; Linessa). As placebo oil, saf-
flower oil was chosen to energy balance the c9,t11-CLA
with LA (C18:2n-6, Table 2). For sensory reasons, the
oils were emulsified in pasteurized skimmed milk (1:2,
wt:wt) before stirring into the yoghurt. All processing
steps were carried out in inert gas atmosphere and
under sterile conditions. The study yoghurt was freshly
prepared in 2-week intervals and distributed to the chil-
dren’s homes on the day of preparation. The parents
were instructed to store the yoghurt cups frozen until
consumption. During the study, the participants main-
tained their usual food habits.
At the beginning and at the end of the study, dietary
records on the three preceding days were requested,
lung function parameters were assessed by whole body
plethysmography and spirometry, and venous blood and
24 h-urine samples were collected for further analyses.
Throughout the intervention period, the participants re-
corded daily their PEF data and kept protocol about
their allergy symptoms and demand medication usage.
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collected.
The study was registered at ClinicalTrials.gov as
NCT01026506, was approved by the Ethics Committee of
the Medical Faculty of the Friedrich Schiller University,
Jena (approval no. 2079-07/07) and took place at the
Department of Nutritional Physiology in Jena.
Blood sampling, preparation, and measurements
Prior to and after the 12-week intervention period, per-
ipheral blood was taken for immunological outcome
measures (in vitro cytokine production of leukocytes,
specific IgE, plasma ECP) and metabolic outcome mea-
sures (routine haematological parameters, analysis of
fatty acid profiles of RBC).
In vitro cytokine production
Peripheral blood mononuclear cells (PBMC) were puri-
fied from 9 mL heparin blood by density gradient centri-
fugation. The PBMC interphase was collected, washed
three times with PBS and resuspended in VLE-
RPMI1640 complete medium/3 % autologous serum.
Complete medium contained the following additives:
10 mmol/L HEPES buffer, 2 mmol/L L-alanyl-L-gluta-
min, 50 μg/mL gentamycin (all Biochrom, Berlin,
Germany). 1 × 106 cells/mL were stimulated, according
to the individual allergy, either with IgE-binding capable
recombinant Phl p1 (Biomay, Vienna, Austria), natural
Fel d1 (LTN-FD1-1, Indoor biotechnologies, Warmin-
ster, UK), or natural Der p1 (LTN-DP1-1, Indoor bio-
technologies) at a final concentration of 2 μg/mL.
Corresponding cultures were incubated with the solvent
vehicle. After 48 h incubation under standard culture
conditions, cells were pelleted, and supernatants were
frozen at −80 °C until cytokine analysis with FlowCyto-
mix™ multiplex technology (eBioscience, Frankfurt a.M.,
Germany). The minimum detectable concentration given
by the manufacturer was 4.2 pg/mL for IL-1ß, 16.4 pg/
mL for IL-2, 20.8 pg/mL for IL-4, 1.6 pg/mL for IL-5,
1.2 pg/mL for IL-6, 0.5 pg/mL for IL-8, 1.9 pg/mL for
IL-10, 1.5 pg/mL for IL-12p70, 1.6 pg/mL for IFN-γ,
3.2 pg/mL for TNF-α, and 2.4 pg/mL for TNF-ß. For
some samples, the cytokine concentration assessed on
the basis of the mean fluorescence intensity (MFI) was
near the test sensitivity limit. This mainly concerned IL-
5 and IL-10. In cases where the concentration was below
the linear range of the assay with the calibration curve
being no longer valid, cytokine concentrations in these
samples were assigned the value zero. Thus, to deal with
data that were not normally distributed, we calculated
the absolute difference between study start and study
end values for each subject and compared the study
groups regarding the changes in cytokine concentration.
MFI values for IL-12p70, TNF-α, and TNF-ß were inmost of the samples below the MFI assigned to ‘zero’
and, accordingly, their concentrations not evaluable.
Data were evaluated with the FlowCytomix™ Pro 2.2
Software (Bender MedSystems, Vienna, Austria).
Plasma ECP
Plasma concentration of ECP was quantified using a
commercial ELISA kit (MBL, Nagoya, Japan) with indi-
cated minimum detection limit of 0.125 ng/mL. The
assay was performed according to the manufacturer’s in-
structions. All samples were analyzed in duplicate.
Fatty acid analysis
Assessment of the fatty acid distribution was done on
the basis of the remaining RBC after isolation of PBMC.
Because of their natural numerical ratio of approxi-
mately 1000:1, method-related impurity of RBC due to
granulocytes was considered marginal.
For gas-chromatographic (GC) fatty acid analysis, a
base-catalyzed methylation method was chosen in order
to avoid isomerization of conjugated dienes and produc-
tion of methoxy artefacts [12]. All procedures, GC
conditions, used standards, and data evaluation are de-
scribed in detail elsewhere [13].
Routine haematological parameters
Serum cholesterol, triacylglycerol (TAG), creatinine,
alanine aminotransferase (ALAT), and aspartate amino-
transferase (ASAT) were determined in the routine la-
boratory of the Department of Clinical Medicine and
Laboratory Diagnostics, Friedrich Schiller University of
Jena (Head: Dr. Dr. Michael Kiehntopf ), according to
standard methods of the International Federation of
Clinical Chemistry and Laboratory Medicine.
24 h-urine sampling, preparation, and measurements
At study start and end, urine was collected during the
day before the visits. The participants were instructed to
start collecting after the first urination and to keep the
morning urine of the following day when the visit took
place. 10-mL samples were stored at −80 °C until 8-
oxodG analysis. An aliquot of 2 mL was shipped into the
routine laboratory of the Department of Clinical




a marker of free radical-induced oxidative lesions of nu-
clear and mitochondrial DNA, was determined by means
of HPLC and electrochemical detection as previously de-
scribed [14]. The renal excretion of creatinine, which is
commonly used as reference parameter to adjust for varia-
tions in the glomerular filtration rate, increases with the
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subjects (mean/median: 8.1/8.6 mmol/L) than in females
(6.9/5.7 mmol/L). In order to avoid a possible gender-
caused bias, we therefore related the concentration of 8-
oxodG excreted during the 24-h period of urine collection
to the urine volume and to the body weight (expressed as
nmol/24 h/kg).
Evaluation of 3-days dietary records
In first line, we aimed at assessing the frequency of full
cream milk, cheese, butter, and beef consumption, as
these foods are the main source of dietary CLA. The
per-day uptake of 9,11-CLA was estimated on the basis
of the average content of 9,11-CLA in the lipid fraction
of these foods. Based on published data on the CLA
content of milk fat and beef [15–19], and under the as-
sumption that in 2008 (when the study ran) ca. 98 % of
consumed ruminant foods derived from conventional
feeding conditions and only 2 % from organic pasture
management in Germany, we generated weighed means
of the CLA contents, which we used to estimate the
CLA uptake from dairies and beef. However, due to limi-
tations of the questionnaire on the one hand and consid-
erable natural variations in the CLA content [20] on the
other, it should be emphasized that the herein presented
values for CLA uptake represent only approximations.
For reasons of compliance, the second aim of the dietary
records was to compare the reported liquid intake with
the volume of urine that was collected during the preced-
ing 24-h period. For dietary records, we adapted and
modified a template questionnaire, the so-called ‘Freibur-
ger protocol’. In particular, we extended the inquiry by
more detailed notes on ruminant fat sources and fat con-
tents. Data were evaluated with Prodi® expert software,
version 5.8 (Nutri-Science, Hausach, Germany).
Defining the pollen season
Data on air-borne grass pollen in and around Jena dur-
ing the study was kindly provided by the German ‘Pol-
lenflugdienst’ (pollen counting service, Berlin). The start
and the end of the grass pollen season (of which the tim-
othy grass pollen season was a subset) were defined as
the first and the last 3 consecutive days with ≥5 grains/
m3/24 h, respectively.
Statistics
For the statistical analysis, linear mixed models were
used with the respective outcomes as dependent vari-
ables and study group (CLA vs. placebo), study time
point (study start vs. study end) and an interaction term
between the two factors as independent variables. For
the pulmonary function and immunological readouts
such as in vitro cytokines, the type of allergy (seasonal
vs. all-year) was additionally included as third fixedeffect and the extent of pollination was entered as covar-
iate. Because the subjects underwent examination at two
time points, a subject specific random effect was in-
cluded into all models. Assumptions of these models
were judged by inspection of the conditional studentized
residuals vs. predicted values to assess homoscedasticity
of the residuals and QQ-plot of conditional studentized
residuals to assess normality of the residuals. In case of
the RBC concentrations of c9,c11-CLA and t9,t11-CLA,
these assumptions were not met and, thus, a Generalized
Estimation Equation (GEE) model was applied. When
the interaction between study group, study time point
and/or type of allergy was significant, a posthoc test was
subsequently administered. All calculations were carried
out with SAS 9.4 PROC MIXED and PROC GLIMMIX.
Unless indicated otherwise, data are given as means ±
SD.
Results
All participants who successfully completed the study
reported that they well tolerated the study food. All
measured routine haematological parameters were
within their normal physiological range. The placebo
group had higher TAG values at study start and study
end (Table 3), what was in accordance with the higher
uptake of fat, especially from ruminant sources, in this
group (Table 4). The other parameters were not different
between the study groups or the study time points.
Compliance
The fatty acid profile of the RBC serving as middle-term
marker tissue is commonly used to reflect food-borne
fatty acids. Determining the CLA content of the RBC,
we assessed the bioavailability of the supplemented CLA
oil on one hand and compliance of the participants with
the study diet on the other. The basal level of CLA was
approximately 0.1 % of total fatty acids, whereof c9,t11-
CLA, the predominant naturally occurring isomer,
accounted for almost 100 % (Fig. 2). After 12 weeks of
daily consumption of 3 g 9,11-CLA triacylglycerol, the
total increase in CLA within the lipid fraction of RBC
was 6-fold (p < 0.001). The three 9,11-CLA isomers
showed up in RBC lipids at a ratio of 83:13:3 (c,t:c,c:t,t),
what corresponded well to their ratio in the oil. There
was one sample pair in the CLA group where none of
the isomers increased in the RBC lipids, for why low
compliance of this participant cannot be ruled out.
Estimated CLA uptake from the regular diet
We also estimated the CLA uptake from the regular diet
on the basis of 3-days dietary records. For the assess-
ment of ruminant fat consumption, butter, milk, dairies,
cheese, and beef were factored in. No differences be-
tween the study groups and study time points were
Table 3 Routine haematological parameters
Parameter Placebo CLA P value
Start End Start End gra gr × tib
Cholesterol (mmol/L) 4.48 ± 0.66 4.39 ± 0.78 4.32 ± 0.76 4.29 ± 0.77 0.641 0.779
TAG (mmol/L) 1.28 ± 0.69 1.29 ± 0.96 0.90 ± 0.60 0.92 ± 0.55 0.043 0.494
Creatinine (mmol/L) 66.3 ± 11.6 64.4 ± 9.3 62.3 ± 5.5 63.9 ± 7.9 0.484 0.103
ASAT (μmol/L × s) 0.49 ± 0.11 0.44 ± 0.09 0.49 ± 0.07 0.48 ± 0.08 0.562 0.186
ALAT (μmol/L × s) 0.56 ± 0.13 0.55 ± 0.22 0.53 ± 0.10 0.49 ± 0.09 0.885 0.291
Data are expressed as means ± SD; astudy group (placebo/CLA), bstudy group (placebo/CLA) × study time point (start/end); ALAT – alanine aminotransferase, ASAT
– aspartate aminotransferase, TAG – triacylglycerol
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the macronutrients carbohydrates and protein during
the preceding 3 days prior to the blood sampling. How-
ever, compared to the CLA group, the children of the
placebo group consumed significantly more fat from ru-
minant sources and, accordingly, more CLA (Table 4).
The higher fat intake was reflected by higher TAG levels
in the placebo group at both study time points (Table 3).
As we instructed the participants to maintain their usual
food habits during the study, we assume that the higher
fat intake, especially from ruminant sources, has been
retained throughout the study. This might have been of
relevance for the circulating CLA. However, its content
in the RBC lipids of the placebo group, referred to as
basal level of CLA, was not different from the CLA
group’s basal CLA (Fig. 2).Pulmonary function parameters
Volume parameters
The vital capacity (VC) is the maximum amount of air
that can be expelled from the lungs after a maximum in-
spiration. The addition of VC with the residual volume
(RV) results in the total lung capacity (TLC). The RV is
the gas volume that remains in the lung after maximal
expiration, thereby preventing alveolar collapse. In ob-
structive respiratory disorders RV is elevated by air trap-
ping, which causes pulmonary hyper-inflation [21].Table 4 Uptake of macronutrients, ruminant fat, and diet-derived CL
on the three preceding days prior to blood sampling
Parameter Placebo
Start End
Energy intake (kcal/d) 2087 ± 157 2256 ± 193
Carbohydrates (g/d) 259.8 ± 22.2 278.4 ± 29.7
Protein (g/d) 76.3 ± 7.2 81.3 ± 5.7
Fat (g/d) 79.2 ± 6.7 86.6 ± 7.5
Fat from ruminant sources (g/d) 21.8 ± 3.8 17.7 ± 2.3
CLA (mg/d) 131.1 ± 22.9 104.1 ± 12.6
CLA (mg/100 kcal) 6.1 ± 1.0 4.8 ± 0.5
Data are expressed as means ± SEM; a study group (placebo/CLA), b study group × sFor both volume parameters, no changes were ob-
served when comparing study groups, subgroups based
on the type of allergy, or time points (Table 5).
Flow parameters
The forced expiratory volume in 1 s (FEV1) is the vol-
ume exhaled during the first second of a forced expir-
ation and is given as %FEV predicted, with references
adapted for age, body height and gender. FEV1 is the
most indicative parameter to assess bronchial obstruc-
tion of the airway system by measuring airflow limita-
tions. It is used to diagnose asthma by proving
reversibility of airway obstruction (FEV1 + 12–15 % after
inhalation of bronchodilators) or hyperresponsiveness
(FEV1 – 12–15 % after challenge by specific or unspe-
cific triggers). The maximum midexpiratory flow
(MMEF) is the average expiratory flow between 75 and
25 % of the forced vital capacity (FVC). MMEF is calcu-
lated as ½FVC/Δt, whereby Δt is the time required to
expire the middle half of the FVC. It reflects small air-
way patency and is negatively correlated with severity
and morbidity of asthma.
Independent of the dietary intervention, FEV1 in-
creased significantly (p = 0.041) and MMEF increased by
trend (p = 0.08) over the study period. Post-hoc testing
revealed that this increase was significant in the Phl p1
subgroup (p = 0.039) but not in the Der p1/Fel d1 sub-
group (Table 5). This outcome indicates an improvementA. Per-day values were estimated on the basis of dietary records
CLA P value
Start End gra gr × tib
1846 ± 199 2031 ± 92 0.180 0.963
238.5 ± 25.4 268.3 ± 17.0 0.560 0.788
66.8 ± 7.3 70.9 ± 4.5 0.141 0.936
66.9 ± 9.1 71.4 ± 3.3 0.059 0.841
12.2 ± 1.8 12.5 ± 2.4 0.019 0.330
77.4 ± 11.5 81.3 ± 14.7 0.040 0.254

























Fig. 2 Concentration of 9,11-CLA in RBC. Fatty acid profiles were
determined by GC-FID analysis of cellular lipid extracts and are
expressed as % of total FAME. Data represent means ± SD.
***Significant increase in all 9,11-CLA isomers compared with placebo
and study start (p < 0.001)
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both the CLA and the placebo treatment. Of note, the
Der p1/Fel d1 subgroup started the trial with airflow
values closer to the predicted values than the Phl p1
subgroup.
Disease monitoring parameters
Peak expiratory flow (PEF) and symptom score (patient’s
diaries records)
PEF is the maximum flow generated during forced
expiration following maximal inspiration. For indexing
the activity of the disease process, the individual’s
best value is taken as reference. At the beginning of
the study, the participants received standard peak
flow meters for self-monitoring and daily recording
their PEF data. PEF values obtained in the morning
and the evening of each day were averaged andTable 5 Pulmonary function parameters
Parameter (% predicted) Placebo CLA
Start End Start
FVC
Phl p1 97/94 101/96 96/95
Der p1/Fel d1 97/99 98/100 90/90
RV
Phl p1 106/109 105/120 114/104
Der p1/Fel d1 108/111 123/123 101/95
FEV1
Phl p1 93/91 101/95 95/97
Der p1/Fel d1 104/112 105/114 97/95
MMEF
Phl p1 69/66 76/70 73/69
Der p1/Fel d1 92/93 91/90 87/87
Data are expressed as mean/median; astudy group (placebo/CLA) × study time poin
type of allergy (seasonal/all-year); cseasonal (Phl p1) vs. all-year (Der p1/Fel d1)graphically visualized over the course of the interven-
tion period. The trend in PEF was evaluated accord-
ing to the slope of the fitted straight line (Fig. 3a).
Allergy symptoms were scored by scaling (sudden)
cough, wheezing, and complaints after physical exertion
from ‘0’ (none) over ‘1’ (mild) and ‘2’ (moderate) to ‘3’
(severe). Likewise, daily data over the time course were
fitted to a trend line (Fig. 3b).
Neither PEF nor the symptom score changed in ei-
ther of the study groups or subgroups throughout the
intervention period. Likewise, there were no changes
regarding the usage of demand medication (not
shown).Immunological parameters
Systemic sensitization
Between the start and the end of the study, the mean
specific IgE non-significantly increased 1.4-fold in
both subgroups of the placebo group, ranging from
0.9- to 2.8-fold (not shown). Accordingly, the CAP
class increased in three (all Phl p1) and decreased in
one (Fel d1) of 13 participants of the placebo group
(each by one point, not shown). In the CLA group,
specific IgE remained unchanged in the Der p1/Fel d1
subgroup and increased 1.3-fold in the Phl p1 sub-
group, resulting in reclassification of CAP for six par-
ticipants (two Phl p1 and one Fel d1 increased, and
two Phl p1 and one Der p1 decreased, not shown). In
one participant of the Phl p1 subgroup of the CLA
group, specific IgE increased 10-fold and CAP class
changed accordingly from 3 to 6. Interestingly, this
was the person from whom the RBC lipid fraction
showed no increase in CLA.P value Post-hoc
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Fig. 3 Peak expiratory flow (PEF) and symptom score. The PEF values (a) and allergy symptoms (b) were self-recorded every day by the
participants throughout the study. Of all patient’s diaries, a total of 21 were filled in correctly. Symptom data of a total of 7 participants
(5 of the placebo group) were incomplete and therefore not included. Means are defined by crossmarks
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In general and except for IL-8, cytokine release upon aller-
gen stimulation of PBMC was weak. The maximum con-
centrations detected in supernatants were 140 pg/mL for
IL-1ß, 171 pg/mL for IL-2, 100 pg/mL for IL-4, 228 pg/
mL for IL-5, 167 pg/mL for IL-6, 5140 pg/mL for IL-8,
25 pg/mL for IL-10, and 62 pg/mL for IFN-γ. For IFN-γ
and IL-4, an intervention effect could be described in so
far as these cytokines largely remained unchanged in the



















































Fig. 4 In vitro cytokine production of stimulated PBMC. Box plots depict studplacebo group (p = 0.008 for IFN-γ, and p = 0.052 for IL-4,
Fig. 4). For all the other cytokines, there were no signifi-
cant differences, neither within the groups (start vs. end;
not shown) nor between the groups.Plasma ECP
Plasma eosinophilic cationic protein concentrations did
not differ between the intervention groups. However, an



























y start to study end changes in cytokine release. **p < 0.01, t p = 0.052
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remained unchanged in the CLA group (Fig. 5).
Metabolic parameters
n-6/n-3 PUFA ratio in RBC
The n-6/n-3 PUFA ratio in the RBC lipids was calculated
on the basis of all detectable and identifiable PUFA with
a chain length of C18 up to C22. Although the main
fatty acid in the placebo oil was LA (C18:2n-6), the
mean n-6/n-3 PUFA ratio decreased from 5.7/1 to 5.1/1
in the placebo group (Fig. 6a). The mean ratio in the
CLA group determined at study start was 5.9/1 and im-
proved to 4.8/1 at study end. Comparing study start with
study end, the reduction in the n-6/n-3 PUFA ratio was
significant (p = 0.011; Fig. 6a), irrespective of the type of
intervention and likely due to a general increase in n-3
PUFA in most of the participants (Fig. 6b). Nevertheless,
as a ratio of 5/1 is regarded beneficial in asthmatic pa-
tients [22], the study end status reflected by the RBC
levels was considered as being optimal in both study
groups. Moreover and in contrast to the placebo group,
in the CLA group the PUFA in sum increased by trend
(p = 0.08, 2-tailed student’s t-test, not shown). However,
analysis of dietary records revealed no differences re-
garding the PUFA intake between the study groups at
both study start (CLA: 10 ± 2 g/d; Placebo: 11 ± 1 g/d)
and study end (CLA: 11 ± 1 g/d; Placebo: 11 ± 2 g/d).
Renal excretion of 8-oxodG
Guanin is the DNA base most vulnerable with regard to
oxidation and may easily form 8-oxodG. As a physio-
logical repair mechanism, 8-oxodG is excised and ex-
creted. Hence, urinary 8-oxodG can be regarded as an
indicator of oxidative stress, e.g., due to lipid peroxida-
tion [23].
In both diet groups, the urinary 8-oxodG increased

























Fig. 5 Concentration of plasma ECPHowever, the absolute concentrations as well as the ex-
tent of the increase were not different between the two
groups.
Discussion
Almost all studies on the effects of CLA on immune
function in humans have thus far been conducted on/in
healthy subjects. The first study which addressed the
issue that putative effects of CLA could be more pro-
nounced in situations of immune imbalance, such as al-
lergy, was published in 2008 by Turpeinen et al. [24].
This randomized and placebo-controlled trial in subjects
with birch pollen allergy yielded encouraging results and
indicated modest anti-inflammatory effects of CLA,
when consumed daily at a dose of 2 g during the birch
pollen season. Although lung function parameters have
not been assessed, the aforementioned trial and ours are
reasonably comparable in various aspects. Core
statement of the two studies is that CLA (with c9,t11-
CLA being the major isomer) might not prevent but cer-
tainly dampen the inflammatory response in allergic
subjects. For instance, we herein confirm the finding of
Turpeinen et al. [24] that consumption of CLA resulted
in decreased IFNγ production by stimulated PBMC
(Fig. 4). This is of interest since serum IFNγ was associ-
ated with accelerated lung function decline in asthmatic
patients [25]. Albeit not statistically significant, we
showed a dampening effect of CLA also with regard to
IL-4 and ECP (Figs. 4 and 5). Both mediators are intrin-
sically involved in the pathogenesis and manifestation of
allergy and asthma [26, 27].
Pertaining to the impact of CLA consumption on
human asthma, a prominent study came from
MacRedmond et al. [28]. It demonstrated that supple-
mentation of 4.5 g/d CLA as an adjunct to the usual
care in overweight mild asthmatics for 12 weeks was
associated with improvements in airway hyper-
responsiveness. However, there was no difference in
FEV1, in ß-agonist reversibility, and in parameters of
systemic and airway inflammation between CLA- and
placebo-treated groups [28]. The key finding of an-
other trial in asthmatics was that daily ingestion of
4.8 g CLA for 8 weeks did not attenuate airway in-
flammation or hyperpnea-induced bronchoconstriction
[29]. Of note, in all of the above cited studies CLA
mixtures have been used which contained t10,c12-
CLA in relevant amounts.
Several former studies have investigated the effect of
fatty acid supplementation on asthma, mainly focusing
on n-6 or n-3 fatty acids. The predominant scientific
view is that the trend towards increased consumption of
n-6 fatty acid may have contributed to the rise in the
prevalence of allergic diseases [3]. For instance, in one
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A B
Fig. 6 Ratio of n-6/n-3 PUFA (a) and concentration of n-3 PUFA (b) in RBC. Fatty acid profiles were determined by GC-FID analysis of cellular lipid
extracts. a The ratio was calculated on the basis of C18-22 PUFA. b Means are defined by crossmarks
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acids [30]. Several other studies found that a high intake
of n-6 fatty acids and high serum levels of n-6 fatty acids
were associated with lower FEV1 and increased exhaled
nitric monoxide as surrogate for inflammation [31–33].
In contrast, a substantial number of trials reported that
a diet high in n-3 fatty acids can improve asthma control
[34–39]. However, it is not clear whether this benefit
persists and, more importantly, a comparable number of
studies showed little or no effect for n-3 (reviewed in
[40, 41], and [3]).
In general, the evidence on the relation between indi-
vidual fatty acids and lung function is limited. In the
present study, the higher intake of n-6 fatty acids, mainly
LA, in the placebo group did not impair lung function.
On the contrary, among the children with seasonal al-
lergy, the flow parameters improved in the placebo
group even more clearly than in the CLA group
(Table 5).
In our study, consumption of 3 g 9,11-CLA over a
period of 12 weeks resulted in an increase in n-3 PUFA
in the lipid fraction of RBC (Fig. 6b). We observed this























Fig. 7 Renal excretion of 8-oxodGthe n-3 PUFA in RBC rose upon a 9,11-CLA-enriched
diet [9]. In a study on prenatal nutritional behavior, in
which we analyzed fatty acid profiles in RBC and plasma
of mother-newborn pairs, we found that a maternal diet
high in milk products and, accordingly, high in vaccenic
acid (the precursor of c9,t11-CLA and of t16:1n-7 [42])
was positively associated with both fetal c9,t11-CLA and
fetal long chain n-3 PUFA [43]. To date, it is not clear
how CLA may influence n-3 PUFA. It is conceivable that
this effect is an indirect, as 9,11-CLA enrichment in our
mouse model led to a systemic concentration shift in the
fatty acid profile, largely driven by a percental reduction
in n-6 PUFA [9]. However, there is no plausible explan-
ation for our observation that the n-3 PUFA increased in
the RBC of the placebo group as well. Of course, we
cannot rule out putative effects of other ingredients of
the study yoghurt than the supplemented oils. For in-
stance, an interesting finding of Wall et al. is that oral
administration of probiotics resulted in increased tissue
concentration of n-3 PUFA [44]. The yoghurt we used in
the study was produced with Streptococcus thermophilus
and several Lactobacillus ssp. as starter cultures. Full
particulars were company secret, as we have been in-
formed. Designing the dietary record templates, we fo-
cused on the intake of ruminant foods and less on
dietary sources of n-3 PUFA. Therefore, we have no
exact information on the intake of n-3 PUFA which
could have been considered as confounder. However, the
estimated intake of total PUFA was not different be-
tween the study groups. Yet, we can only speculate that,
likewise, no significant differences have occurred regard-
ing n-6 and n-3 PUFA intake.
In the present study, a triacylglycerol esterified CLA
preparation rich in c9,t11-CLA and free of t10,c12-CLA
was applied [11]. This characteristic of the oil was of
special interest as t10,c12-CLA, accounting for approxi-
mately 50 % of total CLA isomers in commercially avail-
able CLA preparations, is associated with lipodystrophic
alterations and hepatomegalia in rodents (reviewed in
Jaudszus et al. Lipids in Health and Disease  (2016) 15:21 Page 11 of 12[13]). But also in humans, several studies on safety-
assessment revealed unfavorable isomer-specific meta-
bolic effects, namely development of insulin resistance
[45] associated with increased oxidative stress and ele-
vated inflammatory biomarkers [46, 47]. Even a first case
of acute hepatotoxicity after middle-term ingestion of a
preparation containing t10,c12-CLA was described [48].
During the present study, all measured routine parame-
ters remained within their normal physiological range
upon the CLA supplementation and no adverse events
were noticed compared with the placebo.
More often than 8-oxodG, urinary 8-iso-PGF2α (an
isoprostane generated by free-radical induced lipid
oxidation) and/or 15-keto-dihydro-PGF2α (generated
from PGF2α via cyclooxygenase reaction) are used for
the assessment of endogenous oxidative stress due to
lipid peroxidation. It is known that urinary levels of
8-iso-PGF2α and 15-keto-dihydro-PGF2α are in-
creased after CLA supplementation [24, 46, 47],
whereby the pro-oxidative effect seems to be primar-
ily exerted by the t10,c12 isomer of CLA. Other
dietary fatty acids such as LA also induce F2-
isoprostane formation [49]. Moreover, increased lipid
peroxidation-derived DNA damage following high in-
take of LA was described [50]. Park & Floyd [51]
postulated that the formation of 8-oxodG is mediated
by lipid peroxidation products. However, in a study
conducted by Kuhnt et al. with the aim to evaluate
the oxidative stress induced by dietary intake of trans
fatty acids, no association between urinary 8-iso-
PGF2α or 15-keto-dihydro-PGF2α and 8-oxodG was
found [14]. In the present study, excretion of 8-
oxodG was elevated upon 9,11-CLA supplementation
(Fig. 7) what indicates elevated oxidative stress. How-
ever, the increase in urinary 8-oxodG was comparable
with the placebo group, thus likely not specific for
the CLA intervention. Finally, although increased dur-
ing the study, the study end values for 8-oxodG were
still within the normal physiological range [52, 53].
Conclusions
In summary, the findings of this pilot trial indicate a
possible beneficial role of CLA ingestion in asthma on
the cellular level of inflammation. But our data provide
no evidence for a suggested therapy-supporting value of
CLA supplementation in mild asthmatic children at
school age. There is consensus that, in early life, a win-
dow of opportunity exists for imprinting and maturation
of the immune system. It is most likely that the later
development of asthma may be influenced also by
nutritional factors such as ruminant fatty acids [4].
Maybe, intervention strategies should be focused on this
critical time period to be effective in terms of disease
prevention.Abbreviations
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